Go to top of page

Primary tabs

Livestock Systems

Enhancing the management of Antimicrobial Resistance in Fiji

Project Code: LS/2019/119
Budget:
A$2,740,747
Research Program Manager: Dr Anna Okello
Project Leader: Dr Paul De Barro, CSIRO
Duration:
JAN 2020
2020
JUN 2022
Project Status: Legally committed/Active
Key partners
University of Technology – Sydney
University of South Australia
Ministry of Health and Medical Services, Fiji

Overview

This project is enhancing the integrated management of Antimicrobial Resistance (AMR) through existing national structures, resulting in sustainability and improved health outcomes in Fiji.

AMR is recognised as the most urgent emerging threat to human and animal health today. The consequence of AMR is the evolution of ‘superbugs’ that do not respond to standard treatments and therefore cause infections that cannot be treated or contained.

In the Western Pacific region, it is estimated that the economic cost of AMR could be as high as USD1.35 trillion over the next 10 years. Fiji was the first country in the Pacific to develop a three-year National Action Plan against AMR in 2015. Although some progress has been made, there are several priority requirements still to be addressed.

The project team will work to increase the knowledge of both AMR and antimicrobial use in Fiji through a more harmonised interpretation of AMR data across human, animal and environmental sectors.

This project is part of the Research for One Health Systems Strengthening Program co-funded with DFAT addressing zoonoses, antimicrobial resistance and systems strengthening within the Asia Pacific. 

Project outcomes

  • Improved knowledge and evidence on the type, prevalence and risk of AMR across human, animal and environmental settings.
  • Availability of costed policy options for controlling AMR from project risk and economic evaluations, based on accurate AMR risk and economic assessments and harmonised interpretation of the data.
  • Increased skills in detecting AMR across human, animal and environmental settings due to training of laboratory staff.
  • Increased awareness on AMR by both prescribers, end-users and policy makers through project advocacy and campaigns.
  • Improved knowledge on the benefit of AMS including judicious use of antimicrobials and recommendations around updates to existing legislation and regulation to support this.